Instil Bio, Inc. - TIL STOCK NEWS

Instil Bio (NASDAQ: TIL) provided a corporate update and financial results for Q3 2021. Key highlights include the initiation of a Phase 2 trial (DELTA-1) for ITIL-168 in metastatic melanoma after receiving FDA IND clearance and Fast Track Designation. The company reported $20.4 million in cash and cash equivalents with $495 million in marketable securities as of September 30, 2021, enabling operations through 2023. Research and development expenses surged to $29.1 million for Q3 2021, compared to $4.9 million in 2020, reflecting ramped-up clinical efforts.

Instil Bio, Inc. (Nasdaq: TIL) announced the presentation of pre-clinical data for its CoStimulatory Antigen Receptor (CoStAR) platform at the SITC 2021. Key findings indicate that CoStAR significantly enhances the effector function of T cells when combined with tumor-reactive signals. Notably, the anti-FOLR1 CoStAR construct demonstrated over 40% transduction efficiency in primary ovarian cancer TILs. The company looks forward to initiating a Phase 1 study of ITIL-306 in early 2022, with the potential to reduce toxicity associated with high-dose IL-2.

Instil Bio, Inc. (Nasdaq: TIL) announced its participation in two investor conferences in November 2021. The Cowen 5th Annual IO Next Summit is scheduled for November 15, 2021, from 4:45 PM to 5:05 PM ET, with a live session link available. The Jefferies Global Healthcare Conference will be held on November 18, 2021, at 3:00 AM ET, also offering a live session link. An archived replay of both events will be accessible on the company's website for 90 days post-presentation. Instil is dedicated to developing TIL therapies targeting various cancers.

Instil Bio, Inc. (NASDAQ: TIL) presented a subset analysis of treatment outcomes for its TIL therapy at the ESMO Congress 2021. The analysis focused on 12 patients with checkpoint inhibitor-refractory advanced cutaneous melanoma. Among them, 58% achieved an objective response, with a median overall survival of 21.3 months, indicating the potential effectiveness of TIL therapy in difficult cases. The therapy demonstrated manageable side effects, primarily from the pre-treatment regimen. Instil aims to further explore TIL therapy in its upcoming Phase 2 DELTA-1 clinical trial.

Instil Bio (Nasdaq: TIL) has received FDA clearance for its DELTA-1 Phase 2 clinical trial of ITIL-168, aimed at treating patients with advanced melanoma. The trial will focus on patients who have relapsed after PD-1 inhibitors and will include expanded cohorts for those who faced toxicity or had unsatisfactory responses. Topline results are expected in 2023, with potential regulatory submissions for a biologics license application in the U.S. and a marketing authorization in Europe in 2024.

Instil Bio, Inc. (NASDAQ: TIL) announced its participation in two investor conferences this September. The first is the Morgan Stanley 19th Annual Global Healthcare Conference on September 9 at 2:00 p.m. ET, featuring a fireside chat. Following that, Instil will present at Baird’s 2021 Virtual Global Healthcare Conference on September 14 at 5:30 p.m. ET. Live webcasts of these events will be available on the company’s website, with archived recordings accessible after the events.

Instil Bio (NASDAQ: TIL) reported significant clinical advancements in its second quarter 2021 update. In a compassionate use study for advanced melanoma, 67% of patients showed an objective response, with 19% achieving a complete response. The lead asset, ITIL-168, received orphan drug designation from the FDA. Instil is on track to initiate a Phase 2 trial for ITIL-168 in H2 2021 and a Phase 1 trial for ITIL-306 in H1 2022. Financially, cash reserves increased to $566.7 million, supporting operations through 2023.

Instil Bio (Nasdaq: TIL) announced its management will present an overview at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 9:30 a.m. ET. Interested parties can access a live webcast at here. Instil is focused on developing TIL therapies, advancing products like ITIL-168 and ITIL-306 for cancer treatment, particularly advanced melanoma and solid tumors.

Instil Bio (NASDAQ: TIL) reported its Q1 2021 financial results, highlighting a strong IPO with $368 million gross proceeds completed in March 2021. The company is advancing its lead product, ITIL-168, which received orphan drug designation from the U.S. FDA for melanoma. As of March 31, 2021, cash and equivalents reached $609.6 million, allowing operations to be funded into 2023. R&D expenses significantly increased to $14.4 million from $2 million in Q1 2020. The company plans to initiate a Phase 2 trial for ITIL-168 in advanced melanoma in H2 2021.